Abstract
Novel anticoagulants (NOACs) present a huge step forward in better prevention and treatment of pathologic conditions associated with increased coagulation. Their administration is characterized by better predictability of particular effect and lower incidence of adverse drug reactions.
The following article, based on so far published clinical trials, is focusing on the mapping of up-to-date knowledge about direct inhibitor of activated factor Xa, rivaroxaban.